Diabetic Wound Healing: The Peptide Research Landscape

Peptide Wound Healing

15-25% of diabetics develop foot ulcers

Diabetic foot ulcers affect 15-25% of people with diabetes, cost $9-13 billion annually in the US alone, and are the leading cause of non-traumatic amputations worldwide.

Lewis et al., TriNetX Database Study, 2025

Lewis et al., TriNetX Database Study, 2025

View as image

A wound in a person with diabetes exists in a hostile environment. Blood flow to the extremities is compromised by peripheral vascular disease. Neuropathy means the patient may not feel the wound forming or worsening. Hyperglycemia impairs neutrophil function, delays collagen synthesis, and creates a persistent inflammatory state that prevents the wound from progressing through normal healing phases. Bacterial biofilms colonize the wound bed, creating drug-resistant infection reservoirs that antibiotics penetrate poorly. The result: chronic wounds that last months or years, cost billions in healthcare spending, and frequently lead to amputation.

Peptide-based therapies address multiple aspects of this pathology simultaneously: antimicrobial peptides kill biofilm bacteria, growth-factor-mimicking peptides stimulate tissue regeneration, anti-inflammatory peptides modulate the immune response, and hydrogel delivery systems provide sustained peptide release directly at the wound site. For a broader view of peptide-based wound dressings, the technology is advancing faster in diabetic wound research than in any other wound-healing application.

Why Diabetic Wounds Are Different

Normal wound healing proceeds through four overlapping phases: hemostasis (clotting), inflammation (immune cell recruitment), proliferation (new tissue growth), and remodeling (scar maturation). Diabetic wounds stall primarily in the inflammatory phase. High glucose levels lock macrophages in a pro-inflammatory (M1) phenotype, preventing the switch to the pro-healing (M2) phenotype needed for tissue regeneration. Reactive oxygen species accumulate to levels that damage healthy cells rather than just killing bacteria. Matrix metalloproteinases (MMPs) are overexpressed, degrading the extracellular matrix scaffolding that new tissue needs to grow on.

These molecular disruptions create a self-perpetuating cycle. Persistent inflammation prevents healing. The open wound attracts bacterial colonization. Biofilm infection intensifies inflammation. The wound deteriorates rather than progresses.

The numbers are stark. Diabetic foot ulcers affect an estimated 19-34% of people with diabetes over their lifetime. Once a diabetic foot ulcer develops, 10% of patients die within a year. The five-year mortality rate after a major diabetes-related amputation exceeds 50%, worse than many cancers. In the US alone, diabetic wound care costs $9-13 billion annually. These figures make diabetic wound healing one of the largest unmet medical needs in the developed world.

Conventional treatment relies on debridement (removing dead tissue), infection control with antibiotics, offloading (reducing pressure on the wound), and advanced wound dressings. These interventions manage the wound but do not address the underlying molecular failures. The growth factor becaplermin (Regranex) was FDA-approved for diabetic neuropathic ulcers in 1997, but its clinical uptake has been limited by modest efficacy and a black-box warning regarding cancer risk at higher doses. No new wound-healing drug has been approved for diabetic ulcers in the decades since.

Peptides offer the potential to intervene at multiple points in this cycle simultaneously, which is why the field has attracted increasing research attention. Unlike single-mechanism drugs, peptide-based approaches can combine antimicrobial, anti-inflammatory, and pro-regenerative activities within a single molecule or delivery system. The multifunctional nature of many therapeutic peptides is particularly well-suited to a disease where multiple pathological processes occur simultaneously in the same tissue.

Antimicrobial Peptides for Infected Diabetic Wounds

Bacterial infection is the most immediate threat to a diabetic wound. Microbiological studies of chronic diabetic foot ulcers consistently find polymicrobial infection, with an average of 3-5 species per wound. MRSA, Pseudomonas aeruginosa, and Acinetobacter baumannii are the most common drug-resistant organisms. These bacteria form biofilms, structured communities encased in an extracellular polysaccharide matrix that reduces antibiotic penetration by up to 1,000-fold compared to planktonic (free-swimming) bacteria. Standard systemic antibiotics fail to achieve bactericidal concentrations within the biofilm, even when the constituent organisms are technically susceptible in laboratory testing.

Antimicrobial peptides in wound care offer an alternative mechanism: membrane disruption that is inherently difficult for bacteria to develop resistance against. Unlike antibiotics that target specific metabolic pathways, AMPs attack the bacterial membrane itself, a structure that bacteria cannot easily redesign without compromising their own viability.

Lin et al. (2026) optimized TPL6, an antimicrobial peptide gel, specifically for diabetic foot infections. The gel exhibited broad-spectrum activity against drug-resistant microbial strains in preclinical models. The key advance was overcoming the stability and delivery limitations that have prevented most antimicrobial peptides from reaching clinical use. The gel formulation maintained peptide activity at the wound site while protecting it from protease degradation in the wound fluid.^[1]

Feng et al. (2025) took a multifunctional approach by fusing a myristoylated cathelicidin peptide (Cathelicidin-DM) with angiotensin 1-7 (Ang1-7). The resulting self-assembling peptide combined antimicrobial activity from the cathelicidin domain with vascular repair and anti-inflammatory signaling from the Ang1-7 domain. In diabetic wound models, it simultaneously cleared infection, promoted new blood vessel formation, and dampened excessive inflammation.^[2]

Fan et al. (2024) designed a pH-sensitive peptide hydrogel that exploits the acidic microenvironment of infected diabetic wounds (pH 5.5-6.5, compared to pH 7.4 for healthy tissue). The hydrogel remains stable at neutral pH but releases its antimicrobial peptide payload when it contacts the acidic wound bed, providing targeted delivery that minimizes effects on surrounding healthy tissue. The system was effective against drug-resistant biofilm-infected diabetic wounds in animal models.^[3]

Zong et al. (2024) developed an ultrasound-responsive hydrogel incorporating a heparin-binding domain (HBD) peptide. Ultrasound applied to the wound triggers peptide release from the hydrogel, providing on-demand antimicrobial and tissue-repair activity. The externally triggered release addresses a key challenge in chronic wound management: maintaining therapeutic peptide levels over days to weeks without continuous reapplication.^[4]

Peptide Hydrogels for Sustained Delivery

The diabetic wound environment is hostile to therapeutic molecules. Wound exudate dilutes applied drugs. Proteases in wound fluid degrade peptides. Biofilm creates a physical barrier. For peptides to work in this setting, they need delivery systems that protect them from degradation and release them at sustained therapeutic concentrations.

Da et al. (2025) demonstrated that alginate-based hydrogels loaded with antimicrobial peptides maintained sustained release over 14 days in the diabetic wound environment. The alginate matrix protected the peptides from wound-fluid proteases while allowing controlled diffusion into the wound bed. This sustained release is critical because diabetic wounds heal slowly, and a peptide that depletes in 24 hours requires daily dressing changes, which are painful and disruptive to healing tissue.^[5]

Wang et al. (2021) developed ultrashort peptide and hyaluronic acid composite hydrogels as injectable depots for chronic diabetic wound treatment. The self-assembling peptide nanofibers within the hydrogel created a sustained-release matrix that could be injected directly into or around the wound margin, providing mechanical support for tissue regeneration while slowly releasing bioactive cargo.^[6]

Shaw et al. (2025) designed a functional amyloid hydrogel based on peptide self-assembly. In both normal and diabetic rat wound models, the hydrogel enhanced wound healing by mimicking the extracellular matrix. The amyloid-based structure provided a scaffold for cell migration while the peptide components themselves had biological activity, creating a material that is simultaneously structural support and therapeutic agent.^[7]

Du et al. (2026) pushed the complexity further with a 3D-printed chitosan/collagen hydrogel incorporating exosomes and an enzyme/peptide cascade system, all encased in a pH-responsive polydopamine shell. This multi-component system addresses oxidative stress, inflammation, infection, and tissue regeneration simultaneously. Whether the manufacturing complexity is justifiable for clinical use remains to be determined, but the system demonstrates the trend toward multifunctional wound dressings that attack multiple aspects of diabetic wound pathology at once.^[8]

The GLP-1 Connection: Systemic Peptide Therapy for Wound Healing

An unexpected finding has emerged from the GLP-1 receptor agonist literature: patients taking semaglutide or other GLP-1 drugs for diabetes may heal diabetic wounds faster and have lower mortality from foot ulcers.

Bonnet et al. (2026) analyzed the French National Health Data System, covering 51,628 patients with a first diabetic foot ulcer. GLP-1 receptor agonist use was associated with reduced 1-year mortality following the ulcer diagnosis. The effect was independent of glycemic control, suggesting the GLP-1 agonists may influence wound healing through anti-inflammatory or vascular mechanisms beyond blood sugar management.^[9]

Lewis et al. (2025) found similar results in a TriNetX database analysis: semaglutide users showed improved wound healing outcomes in diabetes-related foot ulcers compared to non-users.^[10] Gruzmark et al. (2025) conducted a systematic review of GLP-1 agents in managing diabetic foot ulcers and found consistent signals across multiple observational studies, though no randomized trial has been conducted specifically for this indication.^[11]

The proposed mechanisms include GLP-1 receptor-mediated improvement in microvascular blood flow, anti-inflammatory effects that help resolve the stalled inflammatory phase, and weight loss that reduces mechanical stress on foot ulcers. GLP-1 receptors are expressed on endothelial cells and immune cells involved in wound healing, providing a biological basis for a direct wound-healing effect beyond glycemic control.

The clinical significance of this association is substantial. If GLP-1 agonists improve diabetic wound outcomes, it would represent a rare case of a systemic drug meaningfully affecting a local tissue repair process. The mechanism would also connect peptide-based wound healing to the broader metabolic peptide pharmacology: the same peptide hormone system (incretin signaling) that regulates blood sugar and appetite also influences the vascular and immune processes that govern wound repair.

Whether GLP-1 agonists will eventually gain an indication for wound healing is unknown, but the association is strong enough that it is already influencing prescribing decisions for diabetic patients with active ulcers. Several clinical trials are now planned or underway to test GLP-1 agonists prospectively in diabetic foot ulcer populations, which would provide the randomized evidence needed to establish or refute the observational signal.

What Remains Preclinical

The gap between the preclinical peptide wound literature and clinical practice is substantial. Nearly every study described in this article used animal models (primarily diabetic rodents). No antimicrobial peptide hydrogel for diabetic wounds has completed a human phase 3 trial. The GLP-1 wound healing data comes from observational studies, not randomized trials.

The translation challenges are formidable. Manufacturing peptide hydrogels at the quality and scale required for clinical use is expensive. Regulatory pathways for combination products (peptide + hydrogel + delivery device) are complex. The target population, patients with poorly controlled diabetes and chronic wounds, is difficult to recruit into clinical trials.

GHK-Cu has preclinical wound healing data spanning decades but has not progressed to pivotal clinical trials. The tripeptide (glycyl-histidyl-lysine) copper complex stimulates collagen synthesis, fibroblast proliferation, and angiogenesis in wound models, and it modulates expression of over 4,000 human genes. Despite this extensive mechanistic data, no company has invested in the clinical development pathway needed for FDA approval in diabetic wound healing.

The same translation gap applies to most antimicrobial peptides for wound care. The preclinical evidence is extensive: dozens of AMPs have demonstrated efficacy in diabetic rodent wound models. But the path from rodent wound to human chronic wound is longer than in most therapeutic areas. Rodent wounds heal fundamentally differently from human wounds (contraction versus re-epithelialization), making animal model results less predictive. The heterogeneity of human diabetic wounds, varying by size, location, infection status, vascular supply, and patient comorbidities, makes clinical trial design challenging. And the reimbursement landscape for advanced wound care products is complex, discouraging pharmaceutical investment.

The field needs randomized human data, and obtaining it remains the central challenge. The most promising near-term path may be through the GLP-1 agonists, which are already FDA-approved and widely prescribed, making observational data collection and add-on indication trials more feasible than de novo development of a new peptide wound therapy. For peptide-based approaches to burn treatment, the same translation challenges apply, though the burn wound population is more homogeneous and potentially easier to study.

For more on how chronic wounds resist conventional treatment, the molecular mechanisms of healing failure are increasingly well understood. The peptide-based interventions designed to address those mechanisms are increasingly sophisticated. The missing piece is the clinical evidence that connects the two.

The Bottom Line

Diabetic wound healing represents one of the most active areas in peptide therapeutic research. Antimicrobial peptides that kill biofilm bacteria, self-assembling peptide hydrogels that provide sustained release, pH-responsive and ultrasound-triggered delivery systems, and multifunctional fusion peptides that address infection, inflammation, and tissue repair simultaneously are all in preclinical development. The unexpected association between GLP-1 receptor agonists and improved diabetic foot ulcer outcomes adds a systemic peptide dimension to what has primarily been a topical research field. The clinical translation gap remains wide: no peptide hydrogel for diabetic wounds has completed a phase 3 human trial.

Frequently Asked Questions

Can peptides help heal diabetic wounds?

Preclinical research shows multiple peptide-based approaches can accelerate diabetic wound healing in animal models: antimicrobial peptides clear infection, self-assembling peptide hydrogels provide scaffolds for tissue regeneration, and multifunctional fusion peptides address infection and inflammation simultaneously. No peptide wound therapy has completed a phase 3 human trial for diabetic wounds, so clinical evidence remains limited.

Why do diabetic wounds heal slowly?

Diabetic wounds stall because high glucose impairs immune cell function, keeping macrophages in a pro-inflammatory state. Excess reactive oxygen species damage new tissue. Overexpressed matrix metalloproteinases degrade the extracellular matrix. Poor blood flow from peripheral vascular disease limits oxygen and nutrient delivery. Neuropathy prevents patients from protecting the wound. Bacterial biofilms resist antibiotic treatment and intensify inflammation.

Does Ozempic help with diabetic wound healing?

Observational studies suggest GLP-1 receptor agonists, including semaglutide (Ozempic/Wegovy), are associated with improved wound healing and reduced mortality in diabetic foot ulcer patients. A 2026 French nationwide study of 51,628 patients found GLP-1 agonist use was linked to lower 1-year mortality following foot ulcers. No randomized controlled trial has tested GLP-1 drugs specifically for wound healing.

What antimicrobial peptides are being tested for diabetic wounds?

Several classes are under investigation: cathelicidin derivatives (like the myristoylated Cathelicidin-DM/Ang1-7 fusion peptide), defensin-based peptides (like HBD hydrogels), and synthetic AMPs (like the TPL6 gel). Most are delivered via hydrogel formulations that sustain release over days to weeks. pH-responsive and ultrasound-triggered systems allow targeted delivery specifically at infected wound sites.

What are peptide hydrogels for wound healing?

Peptide hydrogels are water-rich gel materials formed by self-assembling peptide nanofibers. They serve as both wound dressings and drug delivery systems, providing a moist healing environment, a scaffold for cell migration, and sustained release of therapeutic peptides. For diabetic wounds, alginate-based and self-assembling peptide hydrogels have shown sustained antimicrobial release over 14+ days in preclinical studies.

Are there FDA-approved peptide treatments for diabetic foot ulcers?

No peptide-based therapy is specifically FDA-approved for diabetic foot ulcers as of 2026. Becaplermin (Regranex), a recombinant growth factor gel, is approved for diabetic neuropathic ulcers but is a protein, not a peptide. GLP-1 receptor agonists like semaglutide are approved for diabetes and obesity but not for wound healing, though observational data suggests a wound-healing benefit.